
To assess the feasibility and safety of zzso zzso guidance in the placement of zzso central zzso zzso zzso in patients with cancer who had altered zzso zzso 

The study was approved by the institutional review board; informed consent was zzso Medical charts of all patients with cancer who underwent zzso zzso placement at the European Institute of zzso Milan, from September 2001 to August 2008 were zzso zzso Patients were considered to have zzso disorders or risk of bleeding when they had the zzso zzso time more than zzso times normal or activated partial zzso time more than zzso times normal and/or zzso count less than 150 zzso zzso Patients with a zzso time and partial zzso time more than zzso times normal and/or a zzso count less than zzso were considered to be at high risk for zzso Two hundred zzso zzso zzso were placed with US guidance in 157 zzso 

One hundred zzso zzso of 239 zzso zzso were inserted in patients with cancer who had zzso zzso zzso zzso of 122 zzso zzso were implanted in patients considered to be at high risk for zzso All zzso were successfully placed at the first needle pass with no major complications such as bleeding or zzso Two hundred zzso zzso zzso zzso were placed in the zzso zzso and six zzso were placed in the internal jugular zzso No patient underwent any correction for an abnormal zzso zzso 

In patients with cancer who had zzso disorders, zzso zzso placement with US guidance was feasible and safe and did not require correction of zzso zzso 

